June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Intravitreal Panitumumab for Prevention of Myopic Axial Elongation in Highly Myopic Adult Eyes with Myopic Macular Degeneration: Phase 1 Study on Safety
Author Affiliations & Notes
  • Jost Jonas
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Gyulli Kazakbaeva
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Frank G Holz
    Department of Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Songhomitra Panda-Jonas
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Leisan Gilemzianova
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Dinar Khakimov
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Mukharram Bikbov
    Ufa Eye Research Institute, Ufa, Russian Federation
  • Footnotes
    Commercial Relationships   Jost Jonas None; Gyulli Kazakbaeva None; Frank Holz None; Songhomitra Panda-Jonas None; Leisan Gilemzianova None; Dinar Khakimov None; Mukharram Bikbov None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4335 – A0040. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jost Jonas, Gyulli Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan Gilemzianova, Dinar Khakimov, Mukharram Bikbov; Intravitreal Panitumumab for Prevention of Myopic Axial Elongation in Highly Myopic Adult Eyes with Myopic Macular Degeneration: Phase 1 Study on Safety. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4335 – A0040.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recent histomorphometric studies suggested that axial myopic elongation occurs through an equatorial ocular wall enlargement, changing the eye shape from a sphere to a prolate configuration. The equatorial ocular wall enlargement may be achieved by a growth of the equatorial Bruch's membrane (BM), leading to a backward push of the posterior BM and a secondary thinning of the posterior choroid. Since BM is produced by the retinal pigment epithelium, which contains receptors for the epidermal growth factor (EGF) and the in-vitro proliferation of which is supported by EGF, EGF may be a myopic axial elongation-associated messenger molecule. Subsequently, experimental studies in guinea pigs showed that the intravitreal application of blockers of EGF family members and of the EGF receptor led to a decrease in axial elongation, while the intravitreal injection of EGF family members was associated with an increase in axial elongation. The findings suggest that the intravitreal application of EGF receptor blockers such as panitumumab may prevent further axial elongation in adult highly myopic patients. We here examined the safety and tolerability of intravitreally applied panitumumab (Vectibix®).

Methods : The phase 1 study included highly myopic patients with myopic macular degeneration. The eyes received a single intravitreal injection of 0.6 mg (60 µL) panitumumab in a standardized manner.

Results : The study included two patients: Patient #1: male, age: 56 years, best corrected visual acuity (BCVA): 0.05, axial length: 29.10mm, IOP: 12mmHg.; Patient #2: female, age: 68 years, BCVA: 0.12, axial length: 30.86 mm, IOP: 17 mmHg. The examinations performed at one day after the injection did not show any intraocular inflammation or morphological change. Examined at 7 days after the injection, no change was observed in BCVA, retinal electroretinography, perimetry, optical coherence tomography-based clinical histomorphometry of the retina and optic nerve, and intraocular pressure, nor were intraocular signs of inflammation or tissue destruction observed.

Conclusions : The preliminary observations of the first two patients receiving an intravitreal application of the EGF receptor antibody panitumumab do not contradict the assumption of an intraocular tolerability of panitumumab injected in a dose of 0.6 mg.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×